The SELENE study
Prof. Ann Janssens, hematologist at UZ Leuven, discusses the outcomes of the SELENE study for which she was one of the investigators. This phase 3 study evaluated ibrutinib plus bendamustine-rituximab or R-CHOP in previously treated patients with follicular or marginal zone lymphoma to determine if the addition of ibrutinib would prolong progression-free survival.
With the educational support of:
![](https://usercontent.one/wp/medimix.be/wp-content/uploads/sites/5/2023/06/supported-by-icml-2023.png)